Daiichi Sankyo Company, Limited (TYO:4568)
3,585.00
+19.00 (0.53%)
Aug 13, 2025, 3:30 PM JST
Daiichi Sankyo Company Revenue
Daiichi Sankyo Company had revenue of 474.60B JPY in the quarter ending June 30, 2025, with 8.81% growth. This brings the company's revenue in the last twelve months to 1.92T, up 14.09% year-over-year. In the fiscal year ending March 31, 2025, Daiichi Sankyo Company had annual revenue of 1.89T with 17.77% growth.
Revenue (ttm)
1,924.68B
Revenue Growth
+14.09%
P/S Ratio
3.45
Revenue / Employee
97.38M
Employees
19,765
Market Cap
6,635.63B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 1,886.26B | 284.57B | 17.77% |
Mar 31, 2024 | 1,601.69B | 323.21B | 25.28% |
Mar 31, 2023 | 1,278.48B | 233.59B | 22.36% |
Mar 31, 2022 | 1,044.89B | 82.38B | 8.56% |
Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,196.22B |
Takeda Pharmaceutical Company | 4,480.25B |
HOYA Corporation | 876.09B |
Otsuka Holdings | 2,401.70B |
Terumo | 1,037.94B |
Astellas Pharma | 1,944.99B |
Shionogi & | 440.50B |
Olympus | 969.02B |
Daiichi Sankyo Company News
- 11 days ago - Daiichi Sankyo Company, Limited (DSKYF) Q1 FY2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Daiichi Sankyo has inventory buffer, will expand production capacity in Ohio to mitigate US tariffs - CFO - CNBC
- 12 days ago - Daiichi Sankyo reports Q1 results - Seeking Alpha
- 26 days ago - AstraZeneca, Daiichi Sankyo get U.S. breakthrough therapy status for Enhertu - Seeking Alpha
- 26 days ago - ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer - Benzinga
- 7 weeks ago - Daiichi Sankyo, AstraZeneca gets U.S. approval for Datroway - Seeking Alpha
- 7 weeks ago - DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer - Benzinga
- 2 months ago - Targeted cancer drugs may replace chemo for some patients and drugmakers say they're getting closer - CNBC